IMDELLTRA®
(drug powder vial: tarlatamab; stabilizer solution vial: stabilizer solution)
AMGEN
HK Reg. No. HK-68549, HK-68550 (17 Jan, 2025)
Composition:3
• For injection: 1 mg of lyophilized powder in a single-dose vial for reconstitution and further dilution
• For injection: 10 mg of lyophilized powder in a single-dose vial for reconstitution and further dilution
Indication:3
• Imdelltra is indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy*
* This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s)3
References
1. EMC. Letrozole 2.5 mg film-coated tablets SmPC. 30 December 2024. Available from: https://www.medicines.org.uk/emc/product/9957/smpc#gref. [Accessed 19 February 2025]. 2. Sinovac. 23-Valent Pneumococcal Polysaccharide Vaccine. Available from: https://www.sinovac.com/zh-cn/portfolio/ppv23. [Accessed 20 February 2025]. 3. FDA. IMDELLTRA® Highlights of Prescribing Information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761344s000lbl.pdf. [Accessed 20 February 2025]. 4. EMC. Atracurium besilate SmPC. 2 November 2023. Available from: https://www.medicines.org.uk/emc/product/951/smpc#gref. [Accessed 20 February 2025].
